Investment analysts at LADENBURG THALM/SH SH initiated coverage on shares of Jaguar Health (NASDAQ:JAGX) in a research report issued to clients and investors on Thursday, The Fly reports. The brokerage set a “buy” rating on the biotechnology company’s stock.
JAGX has been the subject of several other research reports. HC Wainwright set a $10.00 price target on Jaguar Health and gave the company a “buy” rating in a report on Tuesday, July 2nd. ValuEngine upgraded Jaguar Health from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, Zacks Investment Research cut Jaguar Health from a “buy” rating to a “hold” rating in a report on Thursday, August 15th.
NASDAQ:JAGX opened at $1.10 on Thursday. The company has a current ratio of 0.35, a quick ratio of 0.24 and a debt-to-equity ratio of 0.02. Jaguar Health has a 12-month low of $1.00 and a 12-month high of $175.00. The stock has a 50-day moving average price of $1.36 and a 200 day moving average price of $1.54. The stock has a market capitalization of $52.39 million, a P/E ratio of -0.01 and a beta of 0.74.
In other news, Director James J. Bochnowski purchased 180,582 shares of the business’s stock in a transaction on Tuesday, July 23rd. The stock was acquired at an average price of $2.00 per share, for a total transaction of $361,164.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 1.81% of the company’s stock.
About Jaguar Health
Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.
Recommended Story: Understanding each part of a balance sheet
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.